United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer's scientific expertise to help ensure the continuity of promising clinical development programs of potential future strategic interest t

Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative

BAE Systems PLC

Cisco Systems

CVS Health

Home Depot

JPMorgan Chase & Co

Coca-Cola

For those looking for a steady ride in 2021, today's selection suggests seven blue-chip stocks for consideration in long-term portfolios. The post 7 Blue-Chip Stocks For A Steady-Eddie 2021 appeared first on InvestorPlace.

7 Blue-Chip Stocks For A Steady-Eddie 2021

NVIDIA

Apple

Microsoft

Netflix

Constellation Brands

We have a very interesting week ahead full of earnings reports and news. But time will tell what will happen.

Apple And Nvidia Among Trending Stocks Rated Top Buy This Week

BioNTech SE

Success would help Pfizer and BioNTech compete longer term with J&J and Novavax, whose vaccines don't have the same temperature restrictions.

BioNTech CEO Says a Version of Its Covid Vaccine With Less Stringent Storage Requirements Could Come This Year

AbbVie

Bristol-Myers

Johnson & Johnson

Novartis

Sanofi

Takeda Pharmaceutical

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

The Top 7 Pharmaceutical Stocks for the Next 10 Years

AstraZeneca

Moderna

This past Friday brought the U.S. its largest single-day amount of Covid-19 cases since the pandemic began in earnest back in March of last year: 310K in a single 24-hour period.

Racing Against Time: Covid-19 vs. Vaccines

Public health experts have expressed concern the new mutant strains could pose a threat to inoculation efforts.

BioNTech says Covid vaccine is effective against key new strains; to publish more data in days

Germany's BioNTech SE said Monday it is aiming to supply up to 2 billion doses of its COVID-19 vaccine in 2021, after receiving emergency use authorization in both the U.S. and EU. In a regulatory filing, the company said it has committed to supplying more than 1 billion doses of the vaccine, which it co-developed with Pfizer Inc..

BioNTech to target supply of up to 2 billion doses of COVID-19 vaccine in 2021

GW Pharmaceuticals

Taiwan Semiconductor Manufacturing

Add these top growth stocks to your portfolio before it's too late.

Your 3 Best Profit Opportunities in 2021

Tesla

Every week, Benzinga conducts a survey to collect sentiment on what traders are most excited about, interested in or thinking about when they are managing and building their personal portfolios. This week we posed the following question related to how traders and investors plan to use their stimulus money:

Got $600? Investors Are Buying Stock In Tesla, Nio And Pfizer With Stimulus Checks

Here's how these two huge COVID-19 vaccine makers compare.

Better Coronavirus Stock: AstraZeneca vs. Pfizer

The European Union is planning to double its supply of Pfizer's coronavirus vaccine by purchasing up to 300 million additional doses, officials said Friday. The deal would add to the EU's existing 300 million-dose order — potentially giving the 27-nation bloc nearly half of the 1.3 billion doses that Pfizer and German partner BioNTech plan.

EU looks to buy another 300 million doses of Pfizer COVID vaccine

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- #cureduchenne--CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc's (NYSE: PFE) announcement surrounding the first dosing of a patient with Duchenne in their Phase III gene therapy clinical trial. Pfizer has showcased tremendous progress over the past year in pushing forward PF-06939926, its rAAV9 mini-dystrophin gene therapy for DMD. PF-06939926 was initially developed by Jude Sa

CureDuchenne Congratulates Pfizer on Dosing First Patient in Phase III Clinical Trial for Duchenne Muscular Dystrophy

Aflac

Blackrock Inc

Discover

KeyCorp

Lockheed Martin

Norwood Financial

Realty Income Corp

AT&T

Target

Viatris

Vanguard High Dividend Yield ETF

Growing your dividend income takes time and consistency. In December, we (my wife and I) received a total of $5,483.32 of dividend income.

Dividend Income Summary: Lanny's December 2020 Summary

Pfizer (PFE) doses the first participant in the phase III CIFFREO study, evaluating its investigational gene therapy, PF-06939926, for treating boys with DMD.

Pfizer (PFE) Begins Dosing in DMD Study With Gene Therapy

The European Medicines Agency said Friday that the product information for BioNTech SE and Pfizer Inc.'s COVID-19 vaccine should be updated to say there are six doses in each vial. The authorization granted to the vaccine, which is referred to as Comirnaty in Europe, on Dec. 21 in the European Union says there are five doses in each vial.

Europe's drug regulator says there is an extra dose in BioNTech/Pfizer's COVID-19 vaccine vials

The EU has secured access to 300 million more doses of Pfizer and BioNTech's COVID-19 vaccine, the president of the European Commission, Ursula von der Leyen, said during a press conference Friday morning. This would double the EU's total supply of Pfizer-BioNTech's vaccine, but is unlikely to solve problems with the trade bloc's slow rollout of vaccines.

The EU has secured access to up to 300 million extra Pfizer doses, following criticism for its slow COVID-19 vaccine rollout

The exuberance around the rapid availability of Covid-19 vaccines has been in limbo in recent days. The latest news could offer reassurance.

Pfizer Research Suggests Covid-19 Vaccine Will Protect Against New Variants

The UK's chief medical officers want to delay second doses of the Pfizer/BioNTech vaccine. Is this much ado about nothing for PFE stock?

Pfizer's Covid-19 Vaccine Delay Isn't Welcome News for Shareholders

The Covid-19 vaccine developed by Pfizer and BioNTech appears to provide protection against the new highly contagious U.K. and South African variants, according to a preliminary study.

Pfizer-BioNTech Vaccine Effective Against Mutation in New Covid-19 Variants, Study Finds

BioNTech said that the company would be able to adjust the vaccine developed with Pfizer to address new mutations of a coronavirus if necessary.

Pfizer–BioNTech vaccine appears to protect against U.K. and South African COVID-19 strains, study finds

News for Pfizer Stock (PFE)